BACKGROUND: A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others. The development of effective interventions for social functioning remains a central therapeutic challenge. Cognitive-behavioral social skills training (CBSST) has been found to improve social functioning in schizophrenia, but with only medium effect sizes. Intranasal oxytocin also has prosocial effects, but also only with modest effect sizes. This study assessed whether the addition of intranasal oxytocin to CBSST can strengthen their impact on social function. METHODS: Participants (N = 62) with schizophrenia or schizoaffective disorder entered a 24-week, double-blind, placebo-controlled, randomized clinical trial with a 3-month follow-up evaluation at 2 sites: Maryland and San Diego. Participants were randomized to either intranasal oxytocin 36 IU (3 sprays) twice a day (n = 31) or intranasal placebo-oxytocin (3 sprays) twice a day (n = 31). All participants received CBSST plus a social cognition skills training module (48 total sessions). RESULTS: There were no significant treatment group differences in social functioning, positive symptoms, negative symptoms, defeatist beliefs, or asocial beliefs. The interpretation of treatment effects was complicated by site effects, whereby participants in San Diego began the trial with greater severity of impairments and subsequently showed greater improvements compared with participants in Maryland. CONCLUSIONS: The results did not support the utility of add-on intranasal oxytocin to psychosocial rehabilitation interventions like CBSST for improvement in social function (ClinicalTrials.gov trial number: NCT01752712).
BACKGROUND: A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others. The development of effective interventions for social functioning remains a central therapeutic challenge. Cognitive-behavioral social skills training (CBSST) has been found to improve social functioning in schizophrenia, but with only medium effect sizes. Intranasal oxytocin also has prosocial effects, but also only with modest effect sizes. This study assessed whether the addition of intranasal oxytocin to CBSST can strengthen their impact on social function. METHODS: Participants (N = 62) with schizophrenia or schizoaffective disorder entered a 24-week, double-blind, placebo-controlled, randomized clinical trial with a 3-month follow-up evaluation at 2 sites: Maryland and San Diego. Participants were randomized to either intranasal oxytocin 36 IU (3 sprays) twice a day (n = 31) or intranasal placebo-oxytocin (3 sprays) twice a day (n = 31). All participants received CBSST plus a social cognition skills training module (48 total sessions). RESULTS: There were no significant treatment group differences in social functioning, positive symptoms, negative symptoms, defeatist beliefs, or asocial beliefs. The interpretation of treatment effects was complicated by site effects, whereby participants in San Diego began the trial with greater severity of impairments and subsequently showed greater improvements compared with participants in Maryland. CONCLUSIONS: The results did not support the utility of add-on intranasal oxytocin to psychosocial rehabilitation interventions like CBSST for improvement in social function (ClinicalTrials.gov trial number: NCT01752712).
Authors: David L Roberts; Dennis R Combs; Michael Willoughby; Jim Mintz; Clare Gibson; Betty Rupp; David L Penn Journal: Br J Clin Psychol Date: 2014-01-13
Authors: Gregor Domes; Markus Heinrichs; Andre Michel; Christoph Berger; Sabine C Herpertz Journal: Biol Psychiatry Date: 2006-11-29 Impact factor: 13.382
Authors: Eric Granholm; John R McQuaid; Fauzia Simjee McClure; Lisa A Auslander; Dimitri Perivoliotis; Paola Pedrelli; Thomas Patterson; Dilip V Jeste Journal: Am J Psychiatry Date: 2005-03 Impact factor: 18.112
Authors: Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306
Authors: Michael C Davis; Junghee Lee; William P Horan; Angelika D Clarke; Mark R McGee; Michael F Green; Stephen R Marder Journal: Schizophr Res Date: 2013-05-12 Impact factor: 4.939
Authors: Katie Daughters; D Aled Rees; Laura Hunnikin; Amy Wells; Jeremy Hall; Stephanie van Goozen Journal: Philos Trans R Soc Lond B Biol Sci Date: 2022-07-11 Impact factor: 6.671
Authors: Julia Browne; Philip D Harvey; Robert W Buchanan; Deanna L Kelly; Gregory P Strauss; James M Gold; Jason L Holden; Eric Granholm Journal: Behav Sci (Basel) Date: 2022-02-23